Skip to main content

Table 2 Data for main effects at each measurement point in the trial, by group. Lutein and total zeaxanthin serum data are also included

From: Macular carotenoid supplementation improves disability glare performance and dynamics of photostress recovery

Group

Measure

Baseline

6 months

12 months

Placebo (n = 10)

MPOD

0.527 ± 0.213

0.558 ± 0.222

0.564 ± 0.237

Disability Glare

88.42 ± 58.77

90.63 ± 57.47

91.96 ± 59.12

Photostress recovery (mins)

8.78 ± 5.96

8.84 ± 6.12

8.71 ± 5.79

Serum L (μg/mL)

0.34 ± 0.07

0.35 ± 0.07

0.34 ± 0.08

Serum total Z (μg/mL)

0.13 ± 0.02

0.115 ± 0.03

0.125 ± 0.02

12 mg (n = 24)

MPOD

0.488 ± 0.248

0.586 ± 0.266*

0.654 ± 0.282**

Disability Glare

86.02 ± 55.23

113.55 ± 60.11*

120.43 ± 64.52**

Photostress recovery (mins)

9.11 ± 6.14

7.65 ± 5.41*

6.92 ± 5.09**

Serum L (μg/mL)

0.40 ± 0.08

2.24 ± 0.22*

2.16 ± 0.20**

Serum total Z (μg/mL)

0.10 ± 0.014

0.29 ± 0.03*

0.27 ± 0.03**

24 mg (n = 25)

MPOD

0.511 ± 0.202

0.634 ± 0.271*

0.685 ± 0.289**

Disability Glare

91.8 ± 61.66

123.01 ± 67.43*

128.52 ± 69.96**

Photostress recovery (mins)

9.33 ± 6.39

7.28 ± 5.86*

6.99 ± 5.56*

Serum L (μg/mL)

0.33 ± 0.05

3.25 ± 0.27*

3.29 ± 0.29**

Serum total Z (μg/mL)

0.13 ± 0.01

0.51 ± 0.06*

0.53 ± 0.06**

  1. Based on repeated-measures ANOVA, single asterisk = significant difference from baseline and placebo (p < 0.05); double asterisk = significant difference from baseline, 6-month measure, and placebo (p < 0.05)